AIMS: Previous studies have reported the presence of low-grade inflammation in Alzheimer disease (AD). Based on these data, our work attempts to investigate the effects of some promoter polymorphisms of pro-inflammatory cytokines [interleukin (IL)-1 alpha and IL-1 beta] on AD. PATIENTS AND METHODS: A PCR-RFLP technique was used to analyze the promoter polymorphisms of both IL-1 alpha (-889 C/T) and IL-1 beta (-511 C/T) and the APOE genotype from the DNA samples of 282 patients (according to NINCDS-ADRDA criteria) and 312 control subjects. RESULTS: (i) The risk of developing AD in our population was associated with the IL-1 beta (-511 C/T) promoter polymorphism; (ii) such risk was independent of the risk factor allele in the APOE gene (APOE4); and (iii) the IL-1 alpha promoter polymorphism (-889 C/T) was not associated with the disease. CONCLUSION: In our population, IL-1 beta promoter polymorphism (-511 C/T) is an independent risk factor for AD.
AIMS: Previous studies have reported the presence of low-grade inflammation in Alzheimer disease (AD). Based on these data, our work attempts to investigate the effects of some promoter polymorphisms of pro-inflammatory cytokines [interleukin (IL)-1 alpha and IL-1 beta] on AD. PATIENTS AND METHODS: A PCR-RFLP technique was used to analyze the promoter polymorphisms of both IL-1 alpha (-889 C/T) and IL-1 beta (-511 C/T) and the APOE genotype from the DNA samples of 282 patients (according to NINCDS-ADRDA criteria) and 312 control subjects. RESULTS: (i) The risk of developing AD in our population was associated with the IL-1 beta (-511 C/T) promoter polymorphism; (ii) such risk was independent of the risk factor allele in the APOE gene (APOE4); and (iii) the IL-1 alpha promoter polymorphism (-889 C/T) was not associated with the disease. CONCLUSION: In our population, IL-1 beta promoter polymorphism (-511 C/T) is an independent risk factor for AD.
Authors: K S Benke; M C Carlson; B Q Doan; J D Walston; Q L Xue; A P Reiner; L P Fried; D E Arking; A Chakravarti; M D Fallin Journal: Exp Gerontol Date: 2011-09-24 Impact factor: 4.032
Authors: E Peila; F D'Agata; P Caroppo; L Orsi; P Mortara; S Cauda; M Manfredi; M M Caglio; P Fenoglio; B Baudino; G Castellano; G Bisi; L Pinessi; S Gallone Journal: Neurotox Res Date: 2016-06-07 Impact factor: 3.911
Authors: Julian N Trollor; Evelyn Smith; Emmeline Agars; Stacey A Kuan; Bernhard T Baune; Lesley Campbell; Katherine Samaras; John Crawford; Ora Lux; Nicole A Kochan; Henry Brodaty; Perminder Sachdev Journal: Age (Dordr) Date: 2011-08-19